Deborah J. Andrews - 14 Aug 2026 Form 4 Insider Report for STAAR SURGICAL CO (STAA)

Reporting relationship: Chief Financial Officer & EVP
Issuer ticker: STAA
Reported as of: 14 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Aug 2026, 16:03:06 UTC
Prior SEC filing: 02 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Deborah Andrews

Key filing fact

Deborah J. Andrews filed Form 4 for STAAR SURGICAL CO (STAA) on 18 Aug 2026.

Key facts

This page summarizes Deborah J. Andrews's Form 4 filing for STAAR SURGICAL CO (STAA).
6 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 18 Aug 2026, 16:03.

Change

Previous filing in this sequence was filed on 02 Jul 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001325697 Primary reporting owner

ANDREWS DEBORAH J

Relationship: Chief Financial Officer & EVP
Address: 25510 COMMERCENTRE DRIVE, LAKE FOREST
Signature: /s/ Deborah Andrews
Signature date: 18 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

STAA transaction

Common Stock

Options Exercise

Transaction value
Shares: +5,233
Change %: +14%
Price: $0.000000^*
Shares after: 41,452
Date: 14 Aug 2026
Ownership: Direct

STAA transaction

Common Stock

Tax liability

Transaction value
Shares: -2,662
Change %: -6.4%
Price: $26.18^*
Shares after: 38,910
Date: 14 Aug 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

STAA transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +4,975
Change %
Price: $0.000000^*
Shares after: 4,975
Date: 14 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,975
Exercise price: $0.000000
Footnotes: F2, F3, F4

STAA transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +8,952
Change %
Price: $0.000000^*
Shares after: 8,952
Date: 14 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,952
Exercise price: $26.18
Footnotes: F5

STAA transaction Derivative

Performance Stock Option (right to buy)

Award

Transaction value
Shares: +29,159
Change %
Price: $0.000000^*
Shares after: 29,159
Date: 14 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 29,159
Exercise price: $26.18
Footnotes: F6

STAA transaction Derivative

Performance Stock Units

Options Exercise

Transaction value
Shares: +5,233
Change %: +14%
Price: $0.000000^*
Shares after: 41,452
Date: 14 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,233
Exercise price: $0.000000
Footnotes: F7

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 7 footnotes

Footnote F1

On May 15, 2026, the third tranche of 5,233 performance stock units ("PSUs") awarded to the Reporting Person under the 2025 PSU Program in connection with her new hire grant vested, of which 2,662 shares were withheld to satisfy taxes.

Footnote F2

Each restricted stock unit ("RSU") represents the right to receive one share of STAAR Surgical Company ("Company") common stock upon vesting.

Footnote F3

The Reporting Person was granted Company RSUs on August 14, 2026 (the "Grant Date"). These RSUs vest as to one-third on the first anniversary of the Grant Date, and the remaining two-thirds vesting in 24 substantially equal monthly installments thereafter.

Footnote F4

The Reporting Person was granted Issuer restricted stock units (RSUs) on August 14, 2026 (the "Grant Date"). These RSUs vest as to one-third on the first anniversary of the Grant Date, and the remaining two-thirds vesting in 24 substantially equal monthly installments thereafter.

Footnote F5

The Reporting Person was granted an option to purchase 8,952 shares of Company common stock. The shares underlying the option vest over three years from the Grant Date, with one-third vesting on the first anniversary of the Grant Date and the remaining two-thirds vesting in 24 substantially equal monthly installment thereafter.

Footnote F6

The Reporting Person was granted a performance option to purchase 29,159 shares of Company common stock. The shares underlying the option vest over a performance period ending on the earlier of a change in control and the 10-year anniversary of the Grant Date, subject to achievement of stock-price hurdles of $50.00, $75.00 and $100.00 per share, and time vest as to one-third on the anniversary of the Grant Date with the remaining two-thirds vesting in 24 substantially equal monthly installments thereafter.

Footnote F7

Represents the settlement of the third tranche of PSUs awarded to the Reporting Person in connection with her new hire grant under the 2025 PSU Program. The number of shares earned was determined upon certification by the Compensation Committee based on achievement of applicable performance goals. The original grant was exempt pursuant to Rule 16b-3(d) and was not previously reported.